Indian Journal of Medical and Paediatric Oncology

LinksSchließen

Referenz

Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K. SIGN Study Group.
Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.

Anticancer Drugs 2006;
17: 401-9

Bibliographische Angaben herunterladen

Aufrufen in: